The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
B. Pro
Consultant or Advisory Role - Seattle Genetics (U)
Research Funding - Seattle Genetics
R. Advani
Consultant or Advisory Role - Seattle Genetics
Research Funding - Seattle Genetics
P. Brice
Honoraria - Seattle Genetics
Research Funding - Seattle Genetics
N. Bartlett
Consultant or Advisory Role - Seattle Genetics
Research Funding - Seattle Genetics
J. D. Rosenblatt
Research Funding - Seattle Genetics
T. Illidge
Research Funding - Seattle Genetics
J. Matous
Consultant or Advisory Role - Celgene; Cephalon; Millennium
Research Funding - Seattle Genetics
R. Ramchandren
Research Funding - Seattle Genetics
M. A. Fanale
Consultant or Advisory Role - Seattle Genetics
Research Funding - Seattle Genetics
J. M. Connors
Research Funding - Seattle Genetics
Y. Yang
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
E. L. Sievers
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
D. A. Kennedy
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
A. R. Shustov
Honoraria - Millennium
Research Funding - Seattle Genetics